CCR News and Events

Potent new LDHI inhibitor disrupts tumor growth in mice

Researchers have identified a potent LDH inhibitor, which can disrupt the energy production of tumors in mice. After exposure to the LDH inhibitor, the cancers cells began to rely on a different form of energy production, which could also be disrupted by using a second drug. Combining the two drugs had a potent anti-cancer effect. Read more...

Kenneth Aldape

Kenneth Aldape discusses importance of precise diagnosis in brain and spine tumors

Oct 22, 2019

Kenneth Aldape, M.D., Chief of the Laboratory of Pathology, recently discussed the importance of a precise diagnosis in the treatment of brain and spine tumors in an NCI-CONNECTions blog. In the blog, he shares how he’s using the latest technologies and techniques to provide more individualized care for patients.  Read more...

Andre Nussenzweig

Andre Nussenzweig elected to the National Academy of Medicine

Oct 21, 2019

Andre Nussenzweig, Ph.D., Chief of the Laboratory of Genome Integrity, has been elected to the National Academy of Medicine (NAM), one of the highest honors in the fields of health and medicine. Dr. Nussenzweig was elected to NAM for making seminal discoveries that speak to how cells maintain their own genome stability, allow chromosome fragility and license leukemogenesis at the hands of aberrant DNA repair. Read more...

Large B-cell lymphoma

Clinical trial studies combination therapy for B-cell lymphoma that has spread to the central nervous system

Oct 15, 2019

Mark Roschewski, M.D., Senior Clinician in the Lymphoid Malignancies Branch, is leading a study of a combination therapy to treat aggressive B-cell lymphoma that has spread to the brain and spinal cord. Read more...

Bone anatomy

Clinical trial tests chemotherapy dose for graft-versus-host disease after bone marrow transplant

Oct 11, 2019

The use of cyclophosphamide after hematopoietic cell transplantation (post-transplantation cyclophosphamide) may reduce the risk of severe forms of graft-versus-host disease (GVHD), particularly chronic GVHD. Christopher G. Kanakry, M.D., Investigator in the Experimental Transplantation and Immunology Branch, is conducting a clinical trial to test if an intermediate dose of this drug is better than higher doses as well as evaluating the optimal time to give this drug. Read more...

Tim Greten

Tim Greten discusses liver cancer with OncLive

Oct 7, 2019

Tim Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, was recently interviewed by OncLive. In the interview, Dr. Greten discussed the role of the gut microbiome in antitumor immunity in liver cancer.  Read more...

Amy LeBlanc

Amy LeBlanc discusses how dogs are helping cure childhood cancers

Oct 7, 2019

Amy LeBlanc, D.V.M., Director of the Center for Cancer Research’s Comparative Oncology Program, was recently featured in an Everyday Health article that discusses the importance of studying the connection between cancer in dogs and cancer in children. Dr. LeBlanc says, “By studying [dogs] in the context of clinical trials, it can advance new concepts and better treatment for humans and, potentially, for dogs as patients themselves.” Read more...

Dice falling out of jar

Diversity of liver cancer cells can impede tumors’ response to immunotherapy

Oct 3, 2019

New research from the NCI’s Center for Cancer Research shows that understanding the impacts of cellular diversity on liver tumors’ microenvironment suggests ways to make immunotherapy effective for more patients.   Read more...

Steve Rosenberg

Steve Rosenberg receives Friends of Cancer Research Cancer Leadership Award

Oct 2, 2019

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, recently received the Friends of Cancer Research Cancer Leadership Award. The award recognizes individuals who have been champions for cancer research and steadfast advocates for patients.  Read more...

breast cancer in a dish

Breast Cancer Research

Oct 1, 2019

To recognize Breast Cancer Awareness Month this October, we are highlighting our researchers who are making discoveries in this field. Read more…

Lawrence Samelson

Lawrence Samelson receives Cancer Research Institute Coley Award

Sep 30, 2019

Lawrence Samelson, M.D., Chief of the Laboratory of Cellular and Molecular Biology, was named a recipient of the Cancer Research Institute’s 2019 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. The award recognizes scientists for their seminal discoveries in the fields of basic and tumor immunology.  Read more...

Pages